- Report
- February 2025
- 326 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 144 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- October 2024
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 199 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- August 2024
- 295 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- August 2024
- 128 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Report
- August 2024
- 142 Pages
Middle East, Africa
From €1426EUR$1,500USD£1,198GBP
- Report
- August 2024
- 141 Pages
Europe
From €1426EUR$1,500USD£1,198GBP
- Report
- August 2024
- 142 Pages
Asia Pacific
From €1426EUR$1,500USD£1,198GBP
- Report
- March 2018
- 174 Pages
Global
From €1307EUR$1,375USD£1,098GBP
€2614EUR$2,750USD£2,196GBP
- Report
- December 2023
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2022
- 300 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- August 2022
- 117 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Clinical Trials
- January 2024
- 120 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- September 2023
- 200 Pages
Global
From €3421EUR$3,599USD£2,874GBP

The anti-hypertensive market within the context of cardiovascular drugs is a large and growing sector of the pharmaceutical industry. It includes a wide range of drugs used to treat high blood pressure, including diuretics, beta blockers, ACE inhibitors, calcium channel blockers, and angiotensin receptor blockers. These drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular diseases. They are also used to reduce the risk of kidney disease, which is often associated with high blood pressure.
The anti-hypertensive market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Other companies, such as AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo, also have a presence in the market. Show Less Read more